Get started
Author

Mohammad Atiya

Observed names: Atiya, Mohammad, M. Atiya, Mohammad E. Atiya
OpenAlex ID: A5014425163
Prior Bendamustine (Benda) Exposure Did Not Impact Clinical Outcomes and Decreased CD4+ but Not CD8+ T-Cells in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with the Bispecific Antibody Epcoritamab (Epcor)
2024 · Tycel J. Phillips, Michael Roost Clausen, et al. · Blood · 7
PDF
Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Rituximab Plus Gemcitabine and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Match-Adjusted Comparative Analysis
2025 · Javier Munoz, Allison Rosenthal, et al. · Clinical Lymphoma Myeloma & Leukemia · 2
PDF
Epcoritamab (epcor) + chemoimmunotherapy (CIT) in patients (pts) with relapsed/refractory large B-cell lymphoma (R/R LBCL) eligible for autologous stem cell transplant (ASCT): Pooled results from arms 4 and 10 of EPCORE NHL-2.
2026 · Yasmin Karimi, Pau Abrisqueta, et al. · Journal of Clinical Oncology · 1
ABCL-619: Epcoritamab + Chemoimmunotherapy in Patients With Relapsed/Refractory Large B-Cell Lymphoma Eligible for Autologous Stem Cell Transplant: Pooled Results From Arms 4 and 10 of EPCORE NHL-2
2026 · Yasmin Karimi, Pau Abrisqueta, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: ABCL-619: Epcoritamab + Chemoimmunotherapy in Patients With Relapsed/Refractory Large B-Cell Lymphoma Eligible for Autologous Stem Cell Transplant: Pooled Results From Arms 4 and 10 of EPCORE NHL-2
2026 · Yasmin Karimi, Pau Abrisqueta, et al. · Clinical Lymphoma Myeloma & Leukemia
Durable responses in patients with large B-cell lymphoma and 3+ prior lines of therapy who either paused or discontinued epcoritamab monotherapy while in complete response
2025 · Chan Cheah, Tycel Phillips, et al. · Blood
PDF
Epcoritamab (epcor) monotherapy offers long-term disease control in large B-cell lymphoma (LBCL): NHL-1 subgroup analysis in patients with prior chimeric antigen receptor T-cell (CAR T) therapy from the 3-year follow-up
2025 · Catherine Thieblemont, Wojciech Jurczak, et al. · Blood
PDF
ABCL-1119: Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Glofitamab or Rituximab Plus Gemcitabine and Oxaliplatin in Patients With Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Match-Adjusted Comparative Analysis
2025 · Andrew Ip, Javier Munoz, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: ABCL-370 Novel Analysis of 3-Year Results From the Pivotal EPCORE NHL-1 Study: Outcomes in Patients With Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL) and Complete Response (CR) at 2 Years With Epcoritamab Monotherapy
2025 · Yasmin H. Karimi, Julie M. Vose, et al. · Clinical Lymphoma Myeloma & Leukemia
ABCL-370: Novel Analysis of 3-Year Results From the Pivotal EPCORE NHL-1 Study: Outcomes in Patients With Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL) and Complete Response (CR) at 2 Years With Epcoritamab Monotherapy
2025 · Yasmin H. Karimi, Julie M. Vose, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: ABCL-1119 Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Glofitamab or Rituximab Plus Gemcitabine and Oxaliplatin in Patients With Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Match-Adjusted Comparative Analysis
2025 · Andrew Ip, Javier Munoz, et al. · Clinical Lymphoma Myeloma & Leukemia
Clinical representativeness of pivotal trials for T-cell engagers in relapsed/refractory follicular lymphoma
2025 · Zhijie Ding, Guihua Zhang, et al. · Future Oncology
PDF
659 | Treatment Outcomes in Newly Diagnosed Diffuse Large B‐cell Lymphoma Patients With High Cardiovascular Risk and Treated With Non‐anthracycline–containing Regimens
2025 · J. Darrah, E. Guo, et al. · Hematological Oncology
PDF
423 | ctDNA‐DIRECTED INTERVENTION WITH EPCORITAMAB ALONE OR IN COMBINATION WITH LENALIDOMIDE‐RITUXIMAB IS FEASIBLE IN THE EARLY POST‐CAR‐T POPULATION AT HIGH RISK OF RELAPSE
2025 · M. R. Dowling, S. Inam, et al. · Hematological Oncology
PDF
292 | MATCH‐ADJUSTED COMPARATIVE ANALYSIS OF THE EFFICACY OF EPCORITAMAB + R‐miniCHOP VERSUS R‐miniCHOP IN PREVIOUSLY UNTREATED DIFFUSE LARGE B‐CELL LYMPHOMA
2025 · J. Ďuraš, T. Wang, et al. · Hematological Oncology
PDF
291 | Match‐adjusted Comparison of Epcoritamab Versus Non‐anthracycline Chemoimmunotherapy in Newly Diagnosed Diffuse Large B‐cell Lymphoma Patients With High Cardiovascular Risk
2025 · P. C. Johnson, E. Guo, et al. · Hematological Oncology
PDF
320 | Sustained Remission With Epcoritamab in Relapsed/refractory Large B‐cell Lymphoma: Epcore Nhl‐1 3‐y Results and Analyses in Patients With Complete Response at 2 Y
2025 · C. Y. Cheah, Y. H. Karimi, et al. · Hematological Oncology
PDF
325 | Match‐adjusted Comparative Analysis of Epcoritamab + R‐dhax/c or R‐ice Versus R‐dhax/c or R‐ice in 2l+ Transplant‐eligible Patients With Diffuse Large B‐cell Lymphoma
2025 · J. Darrah, K. Yang, et al. · Hematological Oncology
PDF
Novel analysis of 3-y results from the pivotal EPCORE NHL-1 study: Outcomes in patients (pts) with relapsed/refractory large B-cell lymphoma (R/R LBCL) and complete response (CR) at 2 y with epcoritamab (epcor) monotherapy.
2025 · Yasmin Karimi, Julie Vose, et al. · Journal of Clinical Oncology
Indirect Comparisons of the Efficacy of Epcoritamab Vs Glofitamab in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
2024 · John N. Allan, Christopher P Fox, et al. · Blood
PDF
Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Rituximab, Gemcitabine, and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients: A Match-Adjusted Comparative Analysis
2024 · Javier Munoz, Allison C. Rosenthal, et al. · Blood
PDF
Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Glofitamab or Rituximab Plus Gemcitabine and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients: A Match-Adjusted Comparative Analysis
2024 · Andrew Ip, Javier Munoz, et al. · Blood
PDF
Matching-Adjusted Indirect Treatment Comparison of Epcoritamab Versus Zanubrutinib Plus Obinutuzumab in Relapsed or Refractory Follicular Lymphoma
2024 · Karen Cumings, Viktor Chirikov, et al. · Blood
PDF
Works count: 25
Citation count: 10
H-index: 2
I10-index:
Year
Topic
Type